Last reviewed · How we verify
Guidelines-based antibiotics choice
This is a clinical guideline or protocol for selecting appropriate antibiotics based on evidence-based recommendations, rather than a single drug entity.
This is a clinical guideline or protocol for selecting appropriate antibiotics based on evidence-based recommendations, rather than a single drug entity. Used for Bacterial infections (various types depending on guideline recommendations).
At a glance
| Generic name | Guidelines-based antibiotics choice |
|---|---|
| Sponsor | Osaka General Medical Center |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Guidelines-based antibiotic choice represents a decision-support framework or institutional protocol designed to optimize antibiotic selection according to current clinical evidence, local resistance patterns, and patient factors. It is not a pharmaceutical agent with a defined molecular mechanism, but rather a prescribing approach or clinical tool implemented at Osaka General Medical Center to improve antimicrobial stewardship and reduce inappropriate antibiotic use.
Approved indications
- Bacterial infections (various types depending on guideline recommendations)
Common side effects
Key clinical trials
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (PHASE2, PHASE3)
- Impact of Rapid Pathogen Detection in ICU Patients With Suspected Pneumonia on Antimicrobial Therapy (PHASE2)
- Prescription Support System for Antimicrobial Use in Belgian Primary Care (NA)
- Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis (NA)
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
- Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia (PHASE4)
- INterest of the Negative Predictive Value of Integrons in Choosing a Narrow-spectrum Empirical anTibiotic Treatment vs Usual Empirical Antibiotic Treatment for Urinary Tract infectionS in the PEDiatric Emergency Department (NA)
- Staphylococcus Aureus Network Adaptive Platform Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guidelines-based antibiotics choice CI brief — competitive landscape report
- Guidelines-based antibiotics choice updates RSS · CI watch RSS
- Osaka General Medical Center portfolio CI